Table 1. . Ongoing clinical trials in triple-negative breast cancer.
| Target | Drug | Phase | NCT identifiers | Status |
|---|---|---|---|---|
| BRCA1/2 | ||||
| PARP | Veliparib | Phase I | NCT00892736 | Active, not recruiting |
| Veliparib + chemotherapy | Phase I, II or III | NCT02595905; NCT01251874; NCT01145430; NCT00576654; NCT01818063; NCT02032277 | Recruiting or active, not recruiting | |
| Veliparib + lapatinib (EGFR/HER2i) | Pilot study | NCT02158507 | Recruiting | |
| BGB290 + temozolomide | Phase I – Phase II | NCT03150810 | Recruiting | |
| BMN-673 (talazoparib) | Phase II | NCT02401347 | Recruiting | |
| BMN-673 + carboplatin + paclitaxel | Phase I | NCT02358200 | Active, not recruiting | |
| Rucaparib + cisplatin | Phase II | NCT01074970 | Active, not recruiting | |
| Olaparib | Phase II | NCT02681562; NCT00679783 | Active, not recruiting | |
| Olaparib ± carboplatin ± paclitaxel | Phase I | NCT00516724; NCT01445418; NCT00707707 | Active, not recruiting | |
| Phase II; Phase II – Phase III | NCT02789332; NCT03150576 | Recruiting | ||
| Olaparib ± AZD2014 (mTORi) ± AZD5363 (AKTi) | Phase I – Phase II | NCT02208375 | Recruiting | |
| Olaparib + onalespib (HSP90i) | Phase I | NCT02898207 | Recruiting | |
| Olaparib ± BKM120 (PI3Ki) ± BYL719 (PI3Ki) | Phase I | NCT01623349 | Active, not recruiting | |
| Olaparib + cediranib (VGEFi) | Phase I – Phase II | NCT01116648 | Active, not recruiting | |
| Phase II | NCT02498613 | Recruiting | ||
| Cyclin-dependent kinases | ||||
| CDKs | Dinaciclib + epirubicin | Phase I | NCT01624441 | Active, not recruiting |
| Abemaciclib | Phase II | NCT03130439 | Recruiting | |
| Trilaciclib | Phase II | NCT02978716 | Recruiting | |
| Ribociclib + bicalutamide (ARi) | Phase I – Phase II | NCT03090165 | Recruiting | |
| CHK1 and WEE1 | ||||
| CHK1 | LY2880070 + gemcitabine | Phase I – Phase II | NCT02632448 | Recruiting |
| CHK1/2 | LY2606368 | Phase II | NCT02203513 | Recruiting |
| Wee1 | AZD1775 + cisplatin | Phase II | NCT03012477 | Recruiting |
| AZD1775 | Phase I | NCT02482311 | Active, not recruiting | |
| Growth factors and angiogenesis | ||||
| EGFR | Aftatinib + paclitaxel | Phase II | NCT02511847 | Recruiting |
| Cetuximab + ixabepilone | Phase II | NCT01097642 | Active, not recruiting | |
| Erlotinib + chemotherapy | Phase II | NCT00491816 | Active, not recruiting | |
| Icotinib | Phase II | NCT02362230 | Recruiting | |
| Panitumumab ± cisplatin ± paclitaxel ± carboplatin | Phase II | NCT02546934; NCT02593175; NCT02876107 | Recruiting | |
| HER2 | Trastuzumab + paclitaxel + cyclophosphamide | Phase II | NCT01750073 | Recruiting |
| VEGF | Bevacizumab + paclitaxel | Phase II | NCT01898117 | Recruiting |
| Bevacizumab + paclitaxel + erlotinib (EGFRi) | Phase II | NCT00733408 | Active, not recruiting | |
| VEGFR2 | Apatinib + vinorelbine | Phase II | NCT03254654 | Recruiting |
| Apatinib + fluzoparib (PARPi) | Phase I | NCT03075462 | Recruiting | |
| VEGFR/FGFR | Lucitanib | Phase II | NCT02202746 | Active, not recruiting |
| Androgen receptor | ||||
| Androgen | Enzalutamide | Phase II | NCT02750358 | Recruting |
| NCT01889238 | Active, not recruiting | |||
| Enzalutamide + paclitaxel | Phase IIb | NCT02689427 | Recruting | |
| Bicalutamide | Phase III | NCT03055312 | Recruting | |
| GTx-024 | Phase II | NCT02368691 | Active, not recruiting | |
| CYP17 | VT-464 | Phase II | NCT02130700 | Recruiting |
| PI3K/AKT/mTOR pathway | ||||
| PIK3CA | Taselisib + enzalutamide (ARi) | Phase I – Phase II | NCT02457910 | Recruiting |
| PI3K | BKM120 | Phase II | NCT01790932 | Active, not recruiting |
| BKM120 + MEK162 (MEKi) | Phase I | NCT01363232 | Active, not recruiting | |
| BKM120 + capecitabine + trastuzumab (HER2i) | Phase II | NCT02000882 | Recruiting | |
| AZD8186 | Phase I | NCT01884285 | Recruiting | |
| Gedatolisib + docetaxel + cisplatin + dacomitinib (EGFRi) | Phase I | NCT01920061 | Recruiting | |
| PI3K/mTOR | PQR309 + eribulin | Phase I – Phase II | NCT02723877 | Recruiting |
| Tak-228 (mTORi) + Tak-117 (PI3Ki) + cisplatin + paclitaxel | Phase II | NCT03193853 | Recruiting | |
| Akt | Ipatasertib | Phase II | NCT02162719; NCT02301988 | Active, not recruiting |
| ARQ092 + carboplatin + paclitaxel | Phase Ib | NCT02476955 | Recruiting | |
| GSK2141795 + trametinib (MEKi) | Phase II | NCT01964924 | Active, not recruiting | |
| mTOR | Everolimus | Phase II | NCT01931163 | Recruiting |
| Everolimus + eribulin | Phase I | NCT02616848 | Recruiting | |
| Everolimus + cisplatin + paclitaxel | Phase I – Phase II | NCT01031446 | Active, not recruiting | |
| Phase I | NCT02120469 | Recruiting | ||
| Everolimus + doxorubicin + bevacizumab (VEGFi) | Phase II | NCT02456857 | Recruiting | |
| Everolimus + cisplatin + paclitaxel | Phase II | NCT02531932 | Recruiting | |
| Everolimus + 5-fluorouracil + epirubicin + cyclophosphamide | Phase II | NCT00499603 | Active, not recruiting | |
| Src and WNT signaling | ||||
| Src | Dasatinib | Phase II | NCT02720185 | Recruiting |
| WNT | PTK7-ADC (WNTi) + gedatolisib (PI3Ki) | Phase I | NCT03243331 | Not yet recruiting |
The representative ongoing clinical trials of targeted therapy, including recruiting and active, not recruiting ones, are summarized based on the data from ClinicalTrials.gov as of 24 August 2017. The trials of evaluating the effect of the combination of targeted therapy and immunotherapy are excluded. The letter i represents inhibitor.